Across TCGA pan-cancer cohorts, DEFB135 RNA is linked to patient survival in 13 of 34 cancer types, making it the most broadly survival-associated DEFB135 data layer compared with 2 for mutation status.
The strongest signal is observed in mesothelioma (MESO), where higher DEFB135 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated DEFB135 expression acts as an unfavorable survival marker, although some lineages such as SARC show a favorable association.
MESO, LUSC, and ESCA are the cancer types where DEFB135 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.